Özcan Met/LinkedIn
Feb 3, 2025, 13:46
Özcan Met: The first patient with melanoma received TILs edited with non-viral CRISPR technology
Özcan Met, Associate Professor and Head of Cell Therapy Unit at National Center for Cancer Immune Therapy, posted on LinkedIn:
“This week, the first patient with melanoma received TILs edited with non-viral CRISPR technology – a truly exciting step forward in cell therapy! As someone deeply involved in academic ATMP development, moments like this a powerful reminder of why we do what we do!
Academic trials play a crucial role in bringing innovative therapies from the lab to the clinic, often paving the way for future breakthroughs. They allow us to explore cutting-edge technologies, refine our approaches, and most importantly, offer new hope to patients.
Well done team!”
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Apr 19, 2025, 22:24
Apr 19, 2025, 22:03
Apr 19, 2025, 21:39
Apr 19, 2025, 21:21
Apr 19, 2025, 21:04
Apr 19, 2025, 20:48
Apr 19, 2025, 20:25
Apr 19, 2025, 19:36
Apr 19, 2025, 19:17
Apr 19, 2025, 19:01